References:
  1. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease.Cell Signal. 2011; 23: 1515-27. doi: 10.1016/j.cellsig.2011.05.004
  2. Fischer-Posovszky P, Tews D, Horenburg S, Debatin KM, Wabitsch M. Differential function of Akt2 and Akt2 in human adipocytes. Mol. Cell. Endocrinol. 2012; 358: 135-143. doi: 10.1016/j.mce.2012.03.018
  3. Wan M, Leavens KF, Saleh D, Easton RM, Guertin DA, Peterson TR, Kaestner KH, Sabatini DM, Birnbaum MJ. Postprandial lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, SREBP1c. Cell Metab. 2011; 14: 516-527. doi:10.1016/j.cmet.2011.09.001.
  4. Arya VB, Flanagan SE, Schober E, Rami-Merhar B, Ellard S, Hussain K. Activating AKT2 mutation: hypoinsulinemic hypoketotic hypoglycemia.J Clin Endocrinol Metab. 2014; 99(2): 391-4. doi: 10.1210/jc.2013-3228.
  5. Dushar M, Nowaczyk J, Pyrzak B, Akopyan H, Smigiel R, Walczak A, Rydzanicz M, Ploski R, Szczaluba K. Efficacy and safety of sirolimus therapy in familial hypoinsulinemic hypoglycemia caused by AKT2 mutation inherited from the mosaic father. Med Genet. 2021; 64(12). doi: 10.1016/j.ejmg.2021.104368.
  6. Garg N, Bademci G, Foster J 2nd, Sıklar Z, Berberoglu M, Tekin M. MORFAN Syndrome: An Infantile Hypoinsulinemic Hypoketotic Hypoglycemia Due to an AKT2 Mutation. J Pediatr. 2015; 167(2): 489-91. doi: 10.1016/j.jpeds.2015.04.069.
  7. Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A, Scott C, Harris J, Smillie BJ, Savage DB, Ramaswami U, De Lonlay P, O’Rahilly S, Barroso I, Semple RK. An activating mutation of AKT2 and human hypoglycemia. Science. 2011;334(6055):474. doi: 10.1126/science.1210878.
  8. Ochoa Molina MF, Poggi H, De Toro V, Mendoza C, Hussain K. Facial Dysmorphic Features in a Patient With Nonketotic Hypoglycemia and a Pathogenic Variant in the AKT2 Gene. AACE Clin Case Rep.2021;8(3):109-112. doi: 10.1016/j.aace.2021.11.006.
  9. Hijazi G, Pai N, Nagy LL, et al. Use of waxy maize heat modified starch in the treatment of children between 2 and 5 years with glycogen storage disease type I: A retrospective study. Mol Genet Metab Rep. 2019; 21:1-6. doi: 10.1016/j.ymgmr.2019.100536
  10. Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children. J Pediatr. 2016 Jan;168:212-219. doi: 10.1016/j.jpeds.2015.09.045.
  11. White MF. The insulin signalling system and the IRS protein.Diabetologia . 1997; 40: S2-S17. doi: 10.1007/s001250051387
  12. Hemmings BA & Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012; 4(9). doi: 10.1101/cshperspect.a011189.
  13. Banerjee I, Salomon-Estebanez M, Shah P, Nicholson J, Cosgrove KE, Dunne MJ. Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia. Diabet Med. 2019; 36(1): 9-21. doi: 10.1111/dme.13823.
  14. Minic M, Rocha N, Harris J, et al. Constitutive Activation of AKT2 in Humans Leads to Hypoglycemia Without Fatty Liver or Metabolic Dyslipidemia. J Clin Endocrinol Metab. 2017;102(8):2914-2921. doi: 10.1210/jc.2017-00768.
  15. Steinkrauss L, Lipman TH, Hendell CD, Gerdes M, Thornton PS, Stanley CA. Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism. J. Pediatr. Nurs. 2005; 20(2); 109-118.
  16. Parker VER, Keppler-Noreuil KM, Faivre L, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.Genet Med . 2019; 21:1189-1198. doi: 10.1038/s41436-018-0297-9
  17. Szymanowski M, Estebanez MS, Padidela R, et al. mTOR inhibitors for the treatment of severe congenital hyperinsulinism: Perspectives on limited therapeutic success. J Clin Endocrinol Metab . 2016; 101(12): 4719-4729. doi: 10.1210/jc.2016-2711
  18. Were FN & Lifschitz C. Complementary feeding: beyond nutrition.Ann Nutr Metab . 2018; 73(1): 20-25. doi: 10.1159/000490084